ArticleCancer diagnosis & prognosis
Real-world Outcomes of First-line Platinum-based Chemotherapy in Patients Aged 80 Years or Older With Metastatic Urothelial Carcinoma.
Article in Cancer diagnosis & prognosis. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/Aim: As populations age, more patients aged ≥80 years with metastatic urothelial carcinoma (mUC) require systemic therapy. However, the efficacy and safety of first-line platinum-based chemotherapy (PBC) in octogenarians remain unclear. This study aimed to describe clinical outcomes in patients aged ≥80 years with mUC eligible for PBC. Patients and Methods: We retrospectively analyzed 30 patients with mUC who received first-line PBC between 2005 and 2022. Patient characteristics, tumour response, treatment-related adverse events (TRAEs), and survival outcomes were assessed. Results: The median age was 83 (range=80-92) years. The bladder and upper urinary tract were the primary tumour site in 17 and 13 patients, respectively. Performance status was 0 or 1 in 15 patients each. Lymph node-only metastasis was present in 18 patients (60%). Regimens included methotrexate, vinblastine, doxorubicin, and cisplatin in six patients and gemcitabine plus platinum in 24; 15 patients received carboplatin. The median number of cycles was three. The objective response and disease control rates were 40% and 76.7%, respectively. Grade ≥3 TRAEs occurred in 23 patients (76.7%), mainly hematologic toxicities (myelosuppression). Dose reduction was required in 21 patients (70%), and treatment was discontinued in 14 (46.7%) because of toxicity or patient preference (7 each). Median progression-free survival and overall survival were 5.2 and 11.3 months, respectively. Conclusion: First-line PBC demonstrated measurable anti-tumour activity in eligible patients aged ≥80 years with mUC. However, myelosuppression often necessitated dose reduction or treatment discontinuation. Thus, PBC in this population warrants careful patient selection and proactive toxicity management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.